Aurora Cannabis Total Revenue

The latest total revenue for ACB is $300M as of June 2026. That compares with $360M in the prior-year period — down 18.7% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Aurora Cannabis's historical trend and sector peers before judging valuation or financial health.

Over the past year, ACB's total revenue moved from $360M to $300M — a 18.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Aurora Cannabis's operating scale or balance-sheet position.

Against Healthcare companies, ACB currently prints $300M for total revenue, while the sector average sits near $110B. That is roughly 99.7% below the sector mean. Large gaps often invite a closer look at Aurora Cannabis's growth, margins, and balance sheet.

A total revenue figure of $300M for ACB is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting ACB's total revenue ($300M), review year-over-year change from $360M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.